Blog
RSS FeedPosted by Michael Wonder on 01 Sep 2016
Elotuzumab in multiple myeloma: additional clinical benefit is not proven
1 September 2016 - The only study available was unsuitable for the benefit assessment. ...
Posted by Michael Wonder on 03 Aug 2016
Ramucirumab in gastric cancer: no sign of an additional clinical benefit
1 August 2016 - Former orphan drug undergoes regular early benefit assessment; submitted studies unsuitable for assessment. ...
Posted by Michael Wonder on 03 Aug 2016
Nivolumab in advanced lung cancer: evidence for significant additional benefits
1 August 2016 - Advantages in overall survival and side effects. ...
Posted by Michael Wonder on 03 Aug 2016
Nivolumab in renal cell carcinoma: indication of additional clinical benefits
1 August 2016 - Benefits in overall survival, morbidity and side effects. ...
Posted by Michael Wonder on 02 Aug 2016
Afatinib dimaleate for patients with advanced squamous cell carcinoma of the lung: additional clinical benefits not there says IQWiG
1 August 2016 - Submitted comparisons for the benefit assessment are unsuitable. ...
Posted by Michael Wonder on 02 Jul 2016
Idelalisib in the second-line treatment in CLL: additional benefits still not seen
1 July 2016 - EMA safety review invokes reassessment but still no relevant data. ...
Posted by Michael Wonder on 02 Jul 2016
Necitumumab in NSCLC: small additional benefit for patients with metastases
1 July 2016 - Survival advantage, but also disadvantages. ...
Posted by Michael Wonder on 15 Jun 2016
Osimertinib mesylate in lung cancer: no assigned additional benefits
15 June 2016 - No direct comparative studies / effects in historical comparisons too small for statements for additional benefits. ...
Posted by Michael Wonder on 02 Jun 2016
Cobimetinib in advanced melanoma with BRAF V600 mutation: added benefit now considerable
2 June 2016 - New analyses from the commenting procedure showed further advantages of the drug. ...
Posted by Michael Wonder on 01 Jun 2016
Ramucirumab in colorectal and lung cancer: some additional benefits, some reductions in benefits
1 June 2016 - Germany's IQWiG has just completed its assessment of Lilly's Cyramza for patients with colorectal cancer or ...
Posted by Michael Wonder on 17 May 2016
Vismodegib for basal cell carcinoma: additional benefits still not seen says Germany's IQWiG
17 May 2016 - Submitted data deemed to be unsuitable. ...
Posted by Michael Wonder on 02 May 2016
Ibrutinib: indication of an additional clinical benefit in one of three therapeutic indications
2 May 2016 - The IQWIG in Germany has found ibrutinib has an additional clinical benefit for certain patients with ...
Posted by Michael Wonder on 08 Apr 2016
Additional benefit of crizotinib for the first-line treatment of bronchial carcinoma is not proven
1 April 2016 - Crizotinib (Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) ...
Posted by Michael Wonder on 19 Mar 2016
Addendum on regorafenib in metastatic colorectal cancer: added benefit no longer proven
17 March 2016 - The drug manufacturer presented further analyses; the additional disadvantages outweigh the survival advantage. ...
Posted by Michael Wonder on 19 Mar 2016
Dabrafenib/trametinib: considerable added benefit for men with advanced melanoma
17 March 2016 - Study data subsequently submitted allow quantification / still major added benefit for women. ...